ID   PLK2_HUMAN              Reviewed;         685 AA.
AC   Q9NYY3; O60679; Q96CV7; Q9UE61;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   02-AUG-2002, sequence version 3.
DT   12-OCT-2022, entry version 191.
DE   RecName: Full=Serine/threonine-protein kinase PLK2;
DE            EC=2.7.11.21;
DE   AltName: Full=Polo-like kinase 2;
DE            Short=PLK-2;
DE            Short=hPlk2;
DE   AltName: Full=Serine/threonine-protein kinase SNK;
DE            Short=hSNK;
DE   AltName: Full=Serum-inducible kinase;
GN   Name=PLK2; Synonyms=SNK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=11696980; DOI=10.3109/10425170109041337;
RA   Liby K., Wu H., Ouyang B., Wu S., Chen J., Dai W.;
RT   "Identification of the human homologue of the early-growth response gene
RT   Snk, encoding a serum-inducible kinase.";
RL   DNA Seq. 11:527-533(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Colon;
RA   Anderson K.M., Nerurkar S.S., Hansbury M.J., Fornwald J., Scott G.,
RA   Bouzyk M., Mui P., Imbrugia C.S., Carlson K., Marshall L.A., Roshak A.K.;
RT   "Identification and characterization of human serum-inducible kinase (SNK),
RT   a novel member of the polo-kinase family of cell cycle regulators:
RT   potential implication for regulation of vascular smooth muscle
RT   proliferation.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 110-408.
RA   Fidler C., Boultwood J., Wang Jabs E., Wainscoat J.S.;
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   INDUCTION.
RX   PubMed=11716500; DOI=10.1006/bbrc.2001.5993;
RA   Shimizu-Yoshida Y., Sugiyama K., Rogounovitch T., Ohtsuru A., Namba H.,
RA   Saenko V., Yamashita S.;
RT   "Radiation-inducible hSNK gene is transcriptionally regulated by p53
RT   binding homology element in human thyroid cells.";
RL   Biochem. Biophys. Res. Commun. 289:491-498(2001).
RN   [7]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15242618; DOI=10.1016/j.cub.2004.06.059;
RA   Warnke S., Kemmler S., Hames R.S., Tsai H.L., Hoffmann-Rohrer U., Fry A.M.,
RA   Hoffmann I.;
RT   "Polo-like kinase-2 is required for centriole duplication in mammalian
RT   cells.";
RL   Curr. Biol. 14:1200-1207(2004).
RN   [8]
RP   DOWN-REGULATION IN B-CELL LYMPHOMAS.
RX   PubMed=16160013; DOI=10.1182/blood-2005-03-1194;
RA   Syed N., Smith P., Sullivan A., Spender L.C., Dyer M., Karran L.,
RA   O'Nions J., Allday M., Hoffmann I., Crawford D., Griffin B., Farrell P.J.,
RA   Crook T.;
RT   "Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent
RT   event in B-cell malignancies.";
RL   Blood 107:250-256(2006).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-210; TRP-503;
RP   HIS-629 AND LYS-631.
RX   PubMed=19001868; DOI=10.4161/cc.7.22.7071;
RA   Cizmecioglu O., Warnke S., Arnold M., Duensing S., Hoffmann I.;
RT   "Plk2 regulated centriole duplication is dependent on its localization to
RT   the centrioles and a functional polo-box domain.";
RL   Cell Cycle 7:3548-3555(2008).
RN   [10]
RP   INDUCTION.
RX   PubMed=18832181; DOI=10.1073/pnas.0808266105;
RA   Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R.T., Chen P., Wang Y., Yan M.,
RA   Qian Z., Neilly M.B., Jin J., Zhang Y., Bohlander S.K., Zhang D.E.,
RA   Larson R.A., Le Beau M.M., Thirman M.J., Golub T.R., Rowley J.D., Chen J.;
RT   "Distinct microRNA expression profiles in acute myeloid leukemia with
RT   common translocations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:15535-15540(2008).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF CENPJ.
RX   PubMed=20531387; DOI=10.1038/emboj.2010.118;
RA   Chang J., Cizmecioglu O., Hoffmann I., Rhee K.;
RT   "PLK2 phosphorylation is critical for CPAP function in procentriole
RT   formation during the centrosome cycle.";
RL   EMBO J. 29:2395-2406(2010).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF NPM.
RX   PubMed=20352051; DOI=10.1371/journal.pone.0009849;
RA   Krause A., Hoffmann I.;
RT   "Polo-like kinase 2-dependent phosphorylation of NPM/B23 on serine 4
RT   triggers centriole duplication.";
RL   PLoS ONE 5:E9849-E9849(2010).
RN   [13]
RP   DOWN-REGULATION IN ACUTE MYELOID LEUKEMIA.
RX   PubMed=21340720; DOI=10.1007/s00277-011-1193-4;
RA   Benetatos L., Dasoula A., Hatzimichael E., Syed N., Voukelatou M.,
RA   Dranitsaris G., Bourantas K.L., Crook T.;
RT   "Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in
RT   acute myeloid leukemia and myelodysplastic syndromes: genetic and
RT   epigenetic interactions.";
RL   Ann. Hematol. 90:1037-1045(2011).
RN   [14]
RP   REVIEW ON FUNCTION.
RX   PubMed=20671765; DOI=10.1038/nrd3184;
RA   Strebhardt K.;
RT   "Multifaceted polo-like kinases: drug targets and antitargets for cancer
RT   therapy.";
RL   Nat. Rev. Drug Discov. 9:643-660(2010).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-14; SER-92; LYS-436 AND LEU-487.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase involved in
CC       synaptic plasticity, centriole duplication and G1/S phase transition.
CC       Polo-like kinases act by binding and phosphorylating proteins are that
CC       already phosphorylated on a specific motif recognized by the POLO box
CC       domains. Phosphorylates CENPJ, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1
CC       and SYNGAP1. Plays a key role in synaptic plasticity and memory by
CC       regulating the Ras and Rap protein signaling: required for
CC       overactivity-dependent spine remodeling by phosphorylating the Ras
CC       activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their
CC       degradation by the proteasome. Conversely, phosphorylates the Rap
CC       activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their
CC       activity. Also regulates synaptic plasticity independently of kinase
CC       activity, via its interaction with NSF that disrupts the interaction
CC       between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown
CC       of AMPAR-mediated current that occludes long term depression. Required
CC       for procentriole formation and centriole duplication by phosphorylating
CC       CENPJ and NPM1, respectively. Its induction by p53/TP53 suggests that
CC       it may participate in the mitotic checkpoint following stress.
CC       {ECO:0000269|PubMed:15242618, ECO:0000269|PubMed:19001868,
CC       ECO:0000269|PubMed:20352051, ECO:0000269|PubMed:20531387}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.21;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.21;
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation of Thr-239. Once
CC       activated, activity is stimulated by binding target proteins (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with NSF; causing NSF dissociation from GRIA2.
CC       Interacts with CIB1 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q9NYY3; Q86Y33: CDC20B; NbExp=3; IntAct=EBI-721354, EBI-10260504;
CC       Q9NYY3; Q9HC77: CENPJ; NbExp=3; IntAct=EBI-721354, EBI-946194;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome, centriole {ECO:0000269|PubMed:15242618,
CC       ECO:0000269|PubMed:19001868}. Cell projection, dendrite {ECO:0000250}.
CC       Note=Localizes to centrosomes during early G1 phase where it only
CC       associates to the mother centriole and then distributes equally to both
CC       mother and daughter centrioles at the onset of S phase.
CC   -!- TISSUE SPECIFICITY: Expressed at higher level in the fetal lung,
CC       kidney, spleen and heart. {ECO:0000269|PubMed:11696980}.
CC   -!- INDUCTION: Directly regulated by p53/TP53. Negatively regulated by miR-
CC       126. {ECO:0000269|PubMed:11716500, ECO:0000269|PubMed:18832181}.
CC   -!- DOMAIN: The POLO box domains act as phosphopeptide-binding module that
CC       recognize and bind serine-[phosphothreonine/phosphoserine]-(proline/X)
CC       motifs. PLK2 recognizes and binds docking proteins that are already
CC       phosphorylated on these motifs, and then phosphorylates them (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Catalytic activity is enhanced by phosphorylation of Thr-239.
CC       {ECO:0000250}.
CC   -!- MISCELLANEOUS: There are indications that PLK2 might act as a tumor
CC       suppressor: PLK2 is significantly down-regulated in a wide range of
CC       acute myeloid leukemias (AMLs) and B-cell lymphomas due to aberrant
CC       cytosine methylation in the CpG island located at the 5' of the PLK2
CC       gene (PubMed:16160013, PubMed:21340720). Moreover, miR-126, a microRNA
CC       that negatively regulates PLK2 is up-regulated in AMLs, suggesting that
CC       PLK2 down-regulation by miR-126 could also contribute to leukemogenesis
CC       (PubMed:18832181). {ECO:0000305|PubMed:16160013,
CC       ECO:0000305|PubMed:18832181, ECO:0000305|PubMed:21340720}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF059617; AAC14573.1; -; mRNA.
DR   EMBL; AF223574; AAF62897.1; -; mRNA.
DR   EMBL; U85755; AAD00575.1; -; mRNA.
DR   EMBL; AC008814; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC013879; AAH13879.1; -; mRNA.
DR   CCDS; CCDS3974.1; -.
DR   RefSeq; NP_001239155.1; NM_001252226.1.
DR   RefSeq; NP_006613.2; NM_006622.3.
DR   PDB; 4I5M; X-ray; 1.80 A; A=57-360.
DR   PDB; 4I5P; X-ray; 1.74 A; A=57-360.
DR   PDB; 4I6B; X-ray; 1.80 A; A=57-360.
DR   PDB; 4I6F; X-ray; 2.90 A; A=57-360.
DR   PDB; 4I6H; X-ray; 1.91 A; A=57-360.
DR   PDB; 4RS6; X-ray; 2.60 A; A/B=451-685.
DR   PDB; 4XB0; X-ray; 2.70 A; A/B=468-685.
DR   PDBsum; 4I5M; -.
DR   PDBsum; 4I5P; -.
DR   PDBsum; 4I6B; -.
DR   PDBsum; 4I6F; -.
DR   PDBsum; 4I6H; -.
DR   PDBsum; 4RS6; -.
DR   PDBsum; 4XB0; -.
DR   AlphaFoldDB; Q9NYY3; -.
DR   SMR; Q9NYY3; -.
DR   BioGRID; 115988; 55.
DR   DIP; DIP-48943N; -.
DR   IntAct; Q9NYY3; 48.
DR   MINT; Q9NYY3; -.
DR   STRING; 9606.ENSP00000274289; -.
DR   BindingDB; Q9NYY3; -.
DR   ChEMBL; CHEMBL5938; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9NYY3; -.
DR   GuidetoPHARMACOLOGY; 2169; -.
DR   iPTMnet; Q9NYY3; -.
DR   PhosphoSitePlus; Q9NYY3; -.
DR   BioMuta; PLK2; -.
DR   DMDM; 22096374; -.
DR   MassIVE; Q9NYY3; -.
DR   MaxQB; Q9NYY3; -.
DR   PaxDb; Q9NYY3; -.
DR   PeptideAtlas; Q9NYY3; -.
DR   PRIDE; Q9NYY3; -.
DR   ProteomicsDB; 83299; -.
DR   Antibodypedia; 4042; 262 antibodies from 31 providers.
DR   DNASU; 10769; -.
DR   Ensembl; ENST00000274289.8; ENSP00000274289.3; ENSG00000145632.15.
DR   GeneID; 10769; -.
DR   KEGG; hsa:10769; -.
DR   MANE-Select; ENST00000274289.8; ENSP00000274289.3; NM_006622.4; NP_006613.2.
DR   UCSC; uc003jrn.4; human.
DR   CTD; 10769; -.
DR   DisGeNET; 10769; -.
DR   GeneCards; PLK2; -.
DR   HGNC; HGNC:19699; PLK2.
DR   HPA; ENSG00000145632; Low tissue specificity.
DR   MalaCards; PLK2; -.
DR   MIM; 607023; gene.
DR   neXtProt; NX_Q9NYY3; -.
DR   OpenTargets; ENSG00000145632; -.
DR   PharmGKB; PA134940798; -.
DR   VEuPathDB; HostDB:ENSG00000145632; -.
DR   eggNOG; KOG0575; Eukaryota.
DR   GeneTree; ENSGT00940000158739; -.
DR   InParanoid; Q9NYY3; -.
DR   OMA; MPEADSN; -.
DR   OrthoDB; 507604at2759; -.
DR   PhylomeDB; Q9NYY3; -.
DR   TreeFam; TF101089; -.
DR   BRENDA; 2.7.11.21; 2681.
DR   PathwayCommons; Q9NYY3; -.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   Reactome; R-HSA-9662834; CD163 mediating an anti-inflammatory response.
DR   SignaLink; Q9NYY3; -.
DR   SIGNOR; Q9NYY3; -.
DR   BioGRID-ORCS; 10769; 11 hits in 1103 CRISPR screens.
DR   ChiTaRS; PLK2; human.
DR   GeneWiki; PLK2; -.
DR   GenomeRNAi; 10769; -.
DR   Pharos; Q9NYY3; Tchem.
DR   PRO; PR:Q9NYY3; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q9NYY3; protein.
DR   Bgee; ENSG00000145632; Expressed in spleen and 194 other tissues.
DR   ExpressionAtlas; Q9NYY3; baseline and differential.
DR   Genevisible; Q9NYY3; HS.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0000922; C:spindle pole; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043008; F:ATP-dependent protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0060292; P:long-term synaptic depression; ISS:UniProtKB.
DR   GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB.
DR   GO; GO:0007613; P:memory; ISS:UniProtKB.
DR   GO; GO:0000278; P:mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0007052; P:mitotic spindle organization; IDA:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0071866; P:negative regulation of apoptotic process in bone marrow cell; IEA:Ensembl.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0010508; P:positive regulation of autophagy; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; HMP:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032486; P:Rap protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0046599; P:regulation of centriole replication; IDA:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB.
DR   CDD; cd13118; POLO_box_1; 1.
DR   CDD; cd13117; POLO_box_2; 1.
DR   CDD; cd14188; STKc_PLK2; 1.
DR   Gene3D; 3.30.1120.30; -; 2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR042825; PLK2_STKc.
DR   InterPro; IPR033701; POLO_box_1.
DR   InterPro; IPR033695; POLO_box_2.
DR   InterPro; IPR000959; POLO_box_dom.
DR   InterPro; IPR036947; POLO_box_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00659; POLO_box; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50078; POLO_BOX; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell projection; Cytoplasm; Cytoskeleton;
KW   Kinase; Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Tumor suppressor.
FT   CHAIN           1..685
FT                   /note="Serine/threonine-protein kinase PLK2"
FT                   /id="PRO_0000086561"
FT   DOMAIN          82..334
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          510..573
FT                   /note="POLO box 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00154"
FT   DOMAIN          606..677
FT                   /note="POLO box 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00154"
FT   REGION          21..70
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          406..433
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        406..420
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        205
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         88..96
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         111
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         239
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P53351"
FT   VARIANT         14
FT                   /note="S -> T (in an ovarian Endometrioid carcinoma sample;
FT                   somatic mutation; dbSNP:rs1404394734)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041023"
FT   VARIANT         92
FT                   /note="G -> S (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041024"
FT   VARIANT         436
FT                   /note="E -> K (in dbSNP:rs55768901)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041025"
FT   VARIANT         487
FT                   /note="P -> L (in dbSNP:rs55645589)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041026"
FT   MUTAGEN         210
FT                   /note="N->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19001868"
FT   MUTAGEN         503
FT                   /note="W->F: Impairs localization to the centrosome and
FT                   centriole duplication; when associated with A-629 and
FT                   M-631."
FT                   /evidence="ECO:0000269|PubMed:19001868"
FT   MUTAGEN         629
FT                   /note="H->A: Impairs localization to the centrosome and
FT                   centriole duplication; when associated with F-503 and
FT                   M-631."
FT                   /evidence="ECO:0000269|PubMed:19001868"
FT   MUTAGEN         631
FT                   /note="K->M: Impairs localization to the centrosome and
FT                   centriole duplication; when associated with F-503 and
FT                   A-631."
FT                   /evidence="ECO:0000269|PubMed:19001868"
FT   CONFLICT        28
FT                   /note="A -> G (in Ref. 1; AAC14573)"
FT                   /evidence="ECO:0000305"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   TURN            76..78
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   STRAND          81..91
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   STRAND          94..101
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   TURN            102..105
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   STRAND          106..114
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           115..118
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           121..134
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   STRAND          145..150
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   STRAND          152..159
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           167..174
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           179..198
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           208..210
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   STRAND          211..213
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   STRAND          219..221
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           224..226
FT                   /evidence="ECO:0007829|PDB:4I5M"
FT   TURN            233..235
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           249..252
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           259..275
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           286..288
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           289..293
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           305..314
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           319..321
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           325..329
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           332..335
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           345..348
FT                   /evidence="ECO:0007829|PDB:4I5P"
FT   HELIX           471..485
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          490..492
FT                   /evidence="ECO:0007829|PDB:4XB0"
FT   STRAND          504..510
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   TURN            511..514
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          515..520
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          525..529
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          534..537
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          541..547
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          553..558
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   HELIX           563..582
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          602..616
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          621..625
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   TURN            626..628
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          631..646
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   STRAND          652..656
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   HELIX           657..663
FT                   /evidence="ECO:0007829|PDB:4RS6"
FT   HELIX           667..680
FT                   /evidence="ECO:0007829|PDB:4RS6"
SQ   SEQUENCE   685 AA;  78237 MW;  6429F6EFD830B333 CRC64;
     MELLRTITYQ PAASTKMCEQ ALGKGCGADS KKKRPPQPPE ESQPPQSQAQ VPPAAPHHHH
     HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT DLTNNKVYAA KIIPHSRVAK
     PHQREKIDKE IELHRILHHK HVVQFYHYFE DKENIYILLE YCSRRSMAHI LKARKVLTEP
     EVRYYLRQIV SGLKYLHEQE ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI
     CGTPNYLSPE VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP
     SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT VPDFHLSSPA
     KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH DLKKTSITQQ PSKHRTDEEL
     QPPTTTVARS GTPAVENKQQ IGDAIRMIVR GTLGSCSSSS ECLEDSTMGS VADTVARVLR
     GCLENMPEAD CIPKEQLSTS FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD
     KKTVHYYAEL GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
     YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR ISTTFRLTTL
     LMSGCSSELK NRMEYALNML LQRCN
//
